Compumedics Limited · ASX:CMP
Compumedics — H1 FY2004 Earnings Presentation
14 slides from Compumedics's earnings presentation, February 2004
Slide 1: Interim Results 6 months ended 31 December 2003
Interim Results 6 months ended 31 December 2003
Slide 2: Outline
Defining Life’s Signals CG courunencs Outline ® Results at 31 December 2003 ® Strategy focused and effective ® Future development
Slide 3: Interim results - Key points
Defining Life’s Signals CG courunencs Interim results - Key points
Slide 4: Key initiatives completed during the six months
Defining Life’s Signals Key initiatives completed during the 6 months ® Focus on profitable growth together with the restructuring of the business has resulted in profits and cash for the period. ® Synamp 2 released to US and ROW Markets June 2003 generates $2.5m in sales in first six months. ® Rema
Slide 5: Historical Sales Graph
Defining Life’s Signals Historical Sales Graph A$m 20 15 TH 1H99 -2H99)«1HOO §=2HOO 1HO] 2HO1 1HO2 2HO2 1HO3 2HO3 1H04 4 Export Sales C1 Domestic Sales [ll Other Income
Slide 6: Regional sales
Defining Life’s Signals CG courunencs Regional sales 2003 Asia Europe 25% Australia 2004 8% : Europe Asia 24% 14% USA 59% Australia 10% USA 52%
Slide 7: A Big Market to Grow In
Defining Life’s Signals CG COMUMEDICS Ge A Big Market to Grow In Estimated global market value = AUD21 21 billion
Slide 8: Performance relative to PCP
Defining Life’s Signals CG courunencs Performance relative to PCP
Slide 9: Balance Sheet relative to PCP
Defining Life’s Signals CG courunencs Balance Sheet relative to PCP
Slide 10: Financial Performance
Defining Life’s Signals CG Financial Performance @ Underlying operating earnings ~ Actual earnings improve due to continued growth in the business and benefits of the restructuring. @ Costs under focus — Actual cash expenses at $8.4m are $1.2m lower than the same time last year on a like for like ba
Slide 11: Moving Forward - Strategy
Defining Life’s Signals Moving Forward - Strategy Grow the business profitably by: ® Growing our global sleep diagnostic business to a leading market share in each of our markets. ® Expanding our Neurological diagnostic business in the USA following the successful development of the business in Aust
Slide 12: To grow the business profitably and to continue to generate cash
Defining Life’s Signals CG To grow the business profitably and to continue to generate cash through improvements in debtor management and inventory turns. Continue to grow the European business by working with Draeger to capture more key sites there. Continuing to grow the sleep business so that it
Slide 13: Moving Forward - Technology
Defining Life’s Signals CG Moving Forward - Technology ® Revised Comperio EMG product to market financial Q4. ® Summit IP released by April 2004. ® Curry software upgrade released financial Q4. @ 128 channel EEG product released by December 2004. @ Second generation Siesta released financial Q4. ® E
Slide 14: Conclusions
Defining Life’s Signals CG courunencs Conclusions 1. Record revenues and profits after tax for six months at $17.3m and $1.1m respectively. 2. Positive operating and net cash for the period. 3. Expanding product offering in growing markets will fuel growth. 4. Profitable growth is the focus.